The DOI matches its Crossref record.
Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma
Abstract
PURPOSE OF REVIEW: The most recent developments regarding chemotherapy treatment of osteogenic sarcoma are reviewed, with special emphasis on prospective clinical trials and evaluations of late effects of chemotherapy. RECENT FINDINGS: In recent years, clinical research has essentially focused on possible refinements of the classic four-drug (methotrexate, cisplatin, doxorubicin and ifosfamide) therapy rather than investigating new drugs. It has been demonstrated that dose-intensification does not improve prognosis. Many investigators have evaluated late chemotherapy-related side effects, particularly in terms of cardiac, renal and auditive toxicity, risk of infertility and of second tumors. Recent findings recommend further studies to define the role of the immunostimulating agent muramyl tripeptide-phosphatidilethanolamine in osteosarcoma. Preclinical and phase II studies suggest an activity of mammalian target of rapamycin (mTOR) inhibitors in osteosarcoma, which also deserves further clinical studies. SUMMARY: At present, patients with nonmetastatic osteosarcoma of the extremity aged less than 40 years have an expected 5-year survival rate of 70% with a chemotherapy regimen based on methotrexate, cisplatin, doxorubicin and ifosfamide. Further improvement cannot be achieved by dose intensification of treatment and new strategies are required. Prolonged follow-up is mandatory due to the risk of late effects, second tumors and late relapse from osteosarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
Osteosarcoma treatment: state of the art
Ta, H. T., Dass, C. R., Choong, P. F. M., & Dunstan, D. E. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9186-7 · Cited by 314
Osteosarcoma: a review of current and future therapeutic approaches
Zhao, X., Wu, Q., Gong, X., Liu, J., & Ma, Y. (2021) · BioMedical Engineering OnLine · doi:10.1186/s12938-021-00860-0 · Cited by 312
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Meazza, C., & Scanagatta, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1168697 · Cited by 298
Ahmed, N., Thompson, E. W., & Quinn, M. A. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21240 · Cited by 237
Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells
Bulut, G., Hong, S.-H., Chen, K., Beauchamp, E. M., Rahim, S., Kosturko, G. W., Glasgow, E., Dakshanamurthy, S., Lee, H.-S., Daar, I., et al. (2012) · Oncogene · doi:10.1038/onc.2011.245 · Cited by 179
Palmerini, E., Jones, R. L., Marchesi, E., Paioli, A., Cesari, M., Longhi, A., Meazza, C., Coccoli, L., Fagioli, F., Asaftei, S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2312-3 · Cited by 98
Palmerini, E., Setola, E., Grignani, G., D’Ambrosio, L., Comandone, A., Righi, A., Longhi, A., Cesari, M., Paioli, A., Hakim, R., et al. (2020) · Cells · doi:10.3390/cells9112389 · Cited by 36
Self-citationPrognostic and clinicopathological significance of circulating tumor cells in osteosarcoma
Li, M., Lu, Y., Long, Z., Li, M., Kong, J., Chen, G., & Wang, Z. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100236 · Cited by 27
Association of circulating tumor cells and IMP3 expression with metastasis of osteosarcoma
Dai, S., Shao, X., Wei, Q., Du, S., Hou, C., Li, H., & Jin, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.819357 · Cited by 20
Metadata
- Authors
- Ferrari, S., & Palmerini, E.
- Venue
- Current Opinion in Oncology
- Published
- 2007-07
- Volume
- 19
- Issue
- 4
- Pages
- 341-346
- ISSN
- 1040-8746 (ISSN-L)
- OpenAlex
- W2010068392
- Cited by
- 219
- References
- 0
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.